When is a TNFi preferred over a JAKi?

TNFi preferred: age ≥65 or high cardiovascular/VTE risk (JAK ORAL Surveillance data), personal or family history of malignancy, active infection risk, pregnancy planning. JAKi preferred: convenience (oral), inadequate TNFi response, seronegative RA, or certain comorbidities.

What are the major JAK inhibitor safety concerns?

Based on ORAL Surveillance: major adverse cardiovascular events (MACE), VTE, malignancy, and serious infections were more frequent with tofacitinib vs adalimumab in RA patients ≥50 with CV risk factors.

Which JAK inhibitors are approved for RA?

FDA-approved JAKi for RA: tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq), filgotinib (Jyseleca, EU only). All carry boxed warning for serious infections, malignancy, and cardiovascular risk.

JAK Inhibitor vs TNF Inhibitor bDMARD Selection Calculator

Guide biologic DMARD selection in rheumatoid arthritis and other inflammatory arthritides. Weighs disease features, comorbidities (cardiovascular risk, VTE risk, malignancy), and drug contraindications against JAKi and TNFi profiles.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.

How to Use

Enter the values for the scenario you are assessing. Guide biologic DMARD selection in rheumatoid arthritis and other inflammatory arthritides. Weighs disease features, comorbidities (cardiovascular risk, VTE risk, malignancy), and drug contraindications against JAKi and TNFi profiles. Use the jak vs tnf bdmard result to inform your calculation.

Related Calculators

DAS28-CRP RA

Hyper-niche Medical